According to the Zhitong Finance App, China Biotech Services (08037.HK) announced interim results for the six months ended June 30, 2026. The group obtained revenue of HK$37.226 million, an increase of 49.71% over the previous year; profit attributable to the owners of the Company was HK$18.23 million, turning a year-on-year loss into a profit; and a profit of HK$0.03 per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.